SCHEDULE: Gilead Sciences Updates Arcus Biosciences Stake to 25.6%
Beneficial Ownership Update (Schedule 13D Amendment)
Gilead Sciences, Inc. has filed an Amendment No. 6 to Schedule 13D, updating its beneficial ownership in Arcus Biosciences, Inc. to 25.6% of outstanding common stock.
Summary
- Gilead Sciences, Inc. beneficially owns 31,424,760 shares of Arcus Biosciences, Inc. common stock.
- This represents 25.6% of Arcus Biosciences' common stock, calculated based on 122,856,086 shares outstanding as of October 31, 2025.
- Gilead's ownership includes shares acquired through various transactions: 2,200,000 shares in the 2020 Public Offering, 5,963,029 shares via the initial Purchase Agreement, 5,650,000 shares via the Amended and Restated Purchase Agreement, 1,010,000 shares via the Second Amended and Restated Purchase Agreement, 15,238,095 shares via the Third Amended and Restated Purchase Agreement, and 1,363,636 shares via a subsequent Public Offering.
- Jeffrey A. Bluestone, a member of Arcus's Scientific Advisory Board, beneficially owns 10,750 shares (0.01%), consisting of options exercisable within 60 days.
- Gilead Sciences, Inc. holds sole voting and dispositive power over its 31,424,760 shares.
Sentiment
Score: 7
Explanation: The filing indicates Gilead's continued and substantial strategic investment in Arcus Biosciences, reinforcing their partnership and commitment, which is generally positive for Arcus. It's a routine update, but the sustained high level of ownership is a positive signal.
Positives
- Gilead Sciences' continued significant beneficial ownership (25.6%) in Arcus Biosciences demonstrates ongoing strategic commitment and confidence in the company.
- The accumulation of shares through multiple agreements and public offerings indicates a sustained investment strategy by Gilead.
Future Outlook
The filing does not contain specific forward-looking statements or guidance regarding future operations or financial performance.
Industry Context
Gilead Sciences' continued accumulation of a significant stake in Arcus Biosciences reflects a broader trend in the pharmaceutical industry where larger companies form strategic alliances or acquire stakes in smaller biotechnology firms to access innovative drug pipelines and expand their therapeutic areas, particularly in oncology.
Related Party Transactions
- Jeffrey A. Bluestone, a member of Arcus Biosciences' Scientific Advisory Board, beneficially owns options to purchase 10,750 shares of Common Stock, received as partial payment for his service.
Stakeholder Impact
- Shareholders of Arcus Biosciences: The continued significant stake by Gilead Sciences reinforces the strategic partnership and potential for future collaboration, which could be viewed positively.
- Shareholders of Gilead Sciences: The filing confirms an ongoing strategic investment in a biotechnology company, aligning with Gilead's broader portfolio strategy.
Key Dates
| Date | Description |
|---|---|
| 2020-07-17 | Initial Schedule 13D filed by Gilead Sciences, Inc. |
| 2021-02-02 | Amendment No. 1 to Schedule 13D filed. |
| 2023-07-06 | Amendment No. 2 to Schedule 13D filed. |
| 2024-01-31 | Amendment No. 3 to Schedule 13D filed. |
| 2025-03-05 | Amendment No. 4 to Schedule 13D filed. |
| 2025-07-15 | Amendment No. 5 to Schedule 13D filed. |
| 2025-10-31 | Date of prospectus supplement filed by Arcus Biosciences, Inc. reporting 122,856,086 shares of Common Stock issued and outstanding. |
| 2025-11-03 | Date of event which requires filing of this statement (Amendment No. 6). |
| 2025-11-05 | Date of signature for Amendment No. 6. |
Recommendation
holdThis Schedule 13D Amendment primarily updates Gilead Sciences' beneficial ownership in Arcus Biosciences, Inc., confirming its substantial and ongoing strategic investment. While Gilead's continued commitment is a positive signal for Arcus, the filing does not introduce new material information that would significantly alter the fundamental investment thesis for either company. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company performance and market conditions rather than this specific ownership update.
Keywords
Gilead Sciences, Arcus Biosciences, Schedule 13D, Beneficial Ownership, Common Stock, Biotechnology, Pharmaceuticals, Strategic Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.